The identification of HLA-C*08:02 restrictions for targeting KRAS G12D neoepitopes heralds an opportunity for potential therapy for common driver mutations in cancers.366 KRAS G12 mutations are commonly found in PDAC, CRC, and NSCLC. This evidence concerns the gene KRAS and colorectal carcinoma.